CO6160325A2 - Moduladores del receptor de progesterona piridooxazepina - Google Patents
Moduladores del receptor de progesterona piridooxazepinaInfo
- Publication number
- CO6160325A2 CO6160325A2 CO09031994A CO09031994A CO6160325A2 CO 6160325 A2 CO6160325 A2 CO 6160325A2 CO 09031994 A CO09031994 A CO 09031994A CO 09031994 A CO09031994 A CO 09031994A CO 6160325 A2 CO6160325 A2 CO 6160325A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound according
- piridooxazepina
- progesterone
- receiver modulators
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto (cis)-8-fluorodibenzo(b,f]pirido[1,2- d]oxazepina-1-amina de acuerdo con Fórmula Ien donde R1 es alquilo (1-4C), opcionalmente sustituido con uno o más átomos de halógeno; y R2 se selecciona del grupo que consiste de H, halógeno, alquilo (1-6C), y CN; y R3, R4, R5 son cada uno independientemente H o F. 2.- Un compuesto de acuerdo con la reivindicación 1 caracterizado porque R2 es H. 3.- Un compuesto de acuerdo con la reivindicación 1 caracterizado porque R2 es CI. 4.- Un compuesto de acuerdo con la reivindicación 1 caracterizado porque R2 es CN. 5.- Un compuesto de acuerdo con las reivindicaciones 1-4 caracterizado porque R3 es H, R4 es H y R5 es H. 6.- Un compuesto da acuerdo con las reivindicaciones 1-4, caracterizado porque R3 es F y R4 y R5 son H. 7.- Un compuesto de acuerdo con las reivindicaciones 1-4, caracterizado porque R4 es F y R3 y R5 son H. 8.- Un compuesto de acuerdo con las reivindicaciones 1-4, caracterizado porque R5 es F y R3 y R4 son H. 9.- Un compuesto de acuerdo con las reivindicaciones 1-8 caracterizado porque R1 es CF3. 10.- Un compuesto de acuerdo con las reivindicaciones 1-8 caracterizado porque R1 es CH3. 11.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es CF3 y cada uno de R2, R3, R4 y R5 es H. 12.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es CH3, R2 es CI y cada uno de R3, R4 y R5 es H. 13.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es CF3, cada uno de R2, R3 y R4 es H, y R5 es F. 14.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es CF3, R2 es CI, R3 y R4 son H, y R5 es F. 15.- Un compuesto de acuerdo con las reivindicaciones 1-14 que es levorotatorio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121372 | 2006-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6160325A2 true CO6160325A2 (es) | 2010-05-20 |
Family
ID=37813577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09031994A CO6160325A2 (es) | 2006-09-27 | 2009-03-27 | Moduladores del receptor de progesterona piridooxazepina |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP2066677B1 (es) |
| JP (1) | JP2010504943A (es) |
| KR (1) | KR20090064454A (es) |
| CN (1) | CN101522689B (es) |
| AR (1) | AR063018A1 (es) |
| AT (1) | ATE478078T1 (es) |
| AU (1) | AU2007302007B2 (es) |
| BR (1) | BRPI0716830A2 (es) |
| CA (1) | CA2664120A1 (es) |
| CL (1) | CL2007002788A1 (es) |
| CO (1) | CO6160325A2 (es) |
| CY (1) | CY1110846T1 (es) |
| DE (1) | DE602007008589D1 (es) |
| DK (1) | DK2066677T3 (es) |
| ES (1) | ES2349325T3 (es) |
| HK (1) | HK1126767A1 (es) |
| HR (1) | HRP20100526T1 (es) |
| IL (1) | IL197365A0 (es) |
| MX (1) | MX2009002804A (es) |
| NO (1) | NO20091016L (es) |
| NZ (1) | NZ575276A (es) |
| PE (1) | PE20071451A1 (es) |
| PL (1) | PL2066677T3 (es) |
| PT (1) | PT2066677E (es) |
| RU (1) | RU2009115643A (es) |
| SI (1) | SI2066677T1 (es) |
| TW (1) | TW200820975A (es) |
| WO (1) | WO2008037746A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297685B (en) | 2002-04-04 | 2008-06-11 | Organon Nv | Non-steroidal progesterone receptor modulators |
| CN101200429B (zh) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法 |
| US8063037B2 (en) | 2007-05-07 | 2011-11-22 | N. V. Organon | Progesterone receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8852901A (en) * | 2000-09-07 | 2002-03-22 | Bayer Corporation | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| TWI297685B (en) * | 2002-04-04 | 2008-06-11 | Organon Nv | Non-steroidal progesterone receptor modulators |
-
2007
- 2007-09-26 DE DE602007008589T patent/DE602007008589D1/de active Active
- 2007-09-26 MX MX2009002804A patent/MX2009002804A/es not_active Application Discontinuation
- 2007-09-26 NZ NZ575276A patent/NZ575276A/en unknown
- 2007-09-26 JP JP2009529699A patent/JP2010504943A/ja not_active Ceased
- 2007-09-26 PT PT07820620T patent/PT2066677E/pt unknown
- 2007-09-26 RU RU2009115643/04A patent/RU2009115643A/ru not_active Application Discontinuation
- 2007-09-26 ES ES07820620T patent/ES2349325T3/es active Active
- 2007-09-26 KR KR1020097007645A patent/KR20090064454A/ko not_active Application Discontinuation
- 2007-09-26 WO PCT/EP2007/060225 patent/WO2008037746A1/en active Application Filing
- 2007-09-26 DK DK07820620.8T patent/DK2066677T3/da active
- 2007-09-26 EP EP07820620A patent/EP2066677B1/en active Active
- 2007-09-26 TW TW096135743A patent/TW200820975A/zh unknown
- 2007-09-26 PL PL07820620T patent/PL2066677T3/pl unknown
- 2007-09-26 CN CN2007800361667A patent/CN101522689B/zh not_active Expired - Fee Related
- 2007-09-26 CA CA002664120A patent/CA2664120A1/en not_active Abandoned
- 2007-09-26 BR BRPI0716830-6A patent/BRPI0716830A2/pt not_active IP Right Cessation
- 2007-09-26 AT AT07820620T patent/ATE478078T1/de active
- 2007-09-26 SI SI200730404T patent/SI2066677T1/sl unknown
- 2007-09-26 AU AU2007302007A patent/AU2007302007B2/en not_active Ceased
- 2007-09-27 CL CL200702788A patent/CL2007002788A1/es unknown
- 2007-09-27 AR ARP070104267A patent/AR063018A1/es not_active Application Discontinuation
- 2007-09-27 PE PE2007001315A patent/PE20071451A1/es not_active Application Discontinuation
-
2009
- 2009-03-03 IL IL197365A patent/IL197365A0/en unknown
- 2009-03-06 NO NO20091016A patent/NO20091016L/no not_active Application Discontinuation
- 2009-03-27 CO CO09031994A patent/CO6160325A2/es unknown
- 2009-06-24 HK HK09105660.9A patent/HK1126767A1/xx not_active IP Right Cessation
-
2010
- 2010-09-24 HR HR20100526T patent/HRP20100526T1/hr unknown
- 2010-10-21 CY CY20101100942T patent/CY1110846T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2664120A1 (en) | 2008-04-03 |
| MX2009002804A (es) | 2009-03-31 |
| KR20090064454A (ko) | 2009-06-18 |
| AU2007302007A1 (en) | 2008-04-03 |
| CN101522689B (zh) | 2012-01-11 |
| AR063018A1 (es) | 2008-12-23 |
| DK2066677T3 (da) | 2010-11-08 |
| PL2066677T3 (pl) | 2011-02-28 |
| JP2010504943A (ja) | 2010-02-18 |
| RU2009115643A (ru) | 2010-11-10 |
| CL2007002788A1 (es) | 2008-04-18 |
| NZ575276A (en) | 2011-07-29 |
| EP2066677B1 (en) | 2010-08-18 |
| IL197365A0 (en) | 2009-12-24 |
| SI2066677T1 (sl) | 2010-12-31 |
| CY1110846T1 (el) | 2015-06-10 |
| ATE478078T1 (de) | 2010-09-15 |
| PT2066677E (pt) | 2010-11-10 |
| NO20091016L (no) | 2009-03-30 |
| WO2008037746A1 (en) | 2008-04-03 |
| DE602007008589D1 (de) | 2010-09-30 |
| BRPI0716830A2 (pt) | 2013-11-05 |
| EP2066677A1 (en) | 2009-06-10 |
| AU2007302007B2 (en) | 2012-02-02 |
| TW200820975A (en) | 2008-05-16 |
| ES2349325T3 (es) | 2010-12-30 |
| HK1126767A1 (en) | 2009-09-11 |
| HRP20100526T1 (hr) | 2010-11-30 |
| PE20071451A1 (es) | 2008-10-30 |
| CN101522689A (zh) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070752A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| PA8843701A1 (es) | Derivados de indolina y métodos para usarlos | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| EA200701853A1 (ru) | Производные циклопентапиридина и тетрагидрохинолина | |
| PA8842501A1 (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
| PA8854001A1 (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
| EA201100303A1 (ru) | Производные пиразоло[5,1-b]оксазола в качестве антагонистов cfr1 | |
| CR9791A (es) | Compuestos de pirimidina como moduladores de receptor de serotonina | |
| NO20093040L (no) | Kinolinderivater som CRTH2 reseptorligander | |
| PE20141169A1 (es) | Derivados de etinilo | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| BRPI0516381A (pt) | derivados de cromano e seu uso como ligandos de receptor de 5-ht | |
| CO6160325A2 (es) | Moduladores del receptor de progesterona piridooxazepina | |
| ECSP12011904A (es) | Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1. | |
| UY29040A1 (es) | Procedimiento de amino-tropano, su preparación y aplicación en terapéutica | |
| CR10780A (es) | Inhibidores de cinasa | |
| AR024747A1 (es) | Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen. | |
| MX2018014684A (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad para el receptor de canabinoide de tipo 2. | |
| UY29879A1 (es) | Derivados de 6-heteroarilpiridoindolona, su preparación y su aplicación en terapéutica | |
| PE20141527A1 (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos | |
| PE20081139A1 (es) | Derivados de cromano, su sintesis e intermediarios | |
| UY32843A (es) | Octasacáridos n-acilos activadores de los receptores de los fgf, su preparación y su aplicación en terapéutica | |
| MX2012007385A (es) | Derivados de aminoalquilpirimidina como anatagonistas del receptor h4 de histamina. |